A bombshell internal memo from the Food and Drug Administration has revealed that the agency’s own vaccine safety experts have identified at least 10 child deaths potentially linked to COVID-19 vaccination, marking the first time federal officials have internally acknowledged fatal outcomes in pediatric patients.
The November 28 memo, exclusively obtained by The Epoch Times, was authored by Dr. Vinay Prasad, who serves as director of the FDA’s Center for Biologics Evaluation and Research (CBER). The document represents what Prasad describes as the agency’s initial internal recognition that COVID-19 vaccines may have caused deadly adverse reactions in children.
According to the memo, career scientists working within the FDA’s vaccine safety divisions have documented “no fewer than 10” pediatric deaths that they believe are connected to COVID-19 vaccination. This acknowledgment comes after years of public assurances from health officials about vaccine safety in children.
The internal document also highlights significant institutional problems within the agency, pointing to what it terms “cultural and systemic” failures that prevented proper investigation of early warning signs. These safety signals allegedly went unexamined for extended periods, raising questions about the FDA’s oversight mechanisms.
The revelation adds new complexity to ongoing debates about COVID-19 vaccine safety, particularly regarding pediatric populations. While health authorities have consistently maintained that serious adverse events are rare, this internal memo suggests that some within the FDA have harbored concerns about fatal outcomes in children that were not previously disclosed to the public.
The timing of this disclosure is particularly significant, as it comes more than three years after COVID-19 vaccines were first authorized for emergency use in adults and nearly two years after they received approval for children as young as six months old.
The memo’s emphasis on systemic failures within the FDA raises broader questions about the agency’s vaccine monitoring processes and whether adequate safeguards were in place to detect and investigate potential safety signals during the rapid vaccine rollout.
This development is likely to intensify scrutiny of federal vaccine safety monitoring systems and may prompt calls for enhanced transparency in how adverse events are tracked, investigated, and reported to the public. The document represents a rare glimpse into internal FDA discussions about vaccine safety concerns that have not been widely shared outside the agency.
